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Abstract
As many as 50% of adults with type I (T1) diabetes exhibit bone loss and are at increased risk for fractures.
Therapeutic development to prevent bone loss and/or restore lost bone in T1 diabetic patients requires
knowledge of the molecular mechanisms accounting for the bone pathology. Because cell culture models
alone cannot fully address the systemic/metabolic complexity of T1 diabetes, animal models are critical.
A variety of models exist including spontaneous and pharmacologically induced T1 diabetic rodents. In
this paper, we discuss the streptozotocin (STZ)-induced T1 diabetic mouse model and examine dose-
dependent effects on disease severity and bone. Five daily injections of either 40 or 60 mg/kg STZ induce
bone pathologies similar to spontaneously diabetic mouse and rat models and to human T1 diabetic bone
pathology. Specifically, bone volume, mineral apposition rate, and osteocalcin serum and tibia messenger
RNA levels are decreased. In contrast, bone marrow adiposity and aP2 expression are increased with either
dose. However, high-dose STZ caused a more rapid elevation of blood glucose levels and a greater mag-
nitude of change in body mass, fat pad mass, and bone gene expression (osteocalcin, aP2). An increase in
cathepsin K and in the ratio of RANKL/OPG was noted in high-dose STZ mice, suggesting the possi-
bility that severe diabetes could increase osteoclast activity, something not seen with lower doses. This
may contribute to some of the disparity between existing studies regarding the role of osteoclasts in di-
abetic bone pathology. Examination of kidney and liver toxicity indicate that the high STZ dose causes
some liver inflammation. In summary, the multiple low-dose STZ mouse model exhibits a similar bone
phenotype to spontaneous models, has low toxicity, and serves as a useful tool for examining mechanisms
of T1 diabetic bone loss.
Key words: streptozotocin; Diabetes mellitus; Type I; bone; mice; osteocalcin; adipocytes;
osteoporosis.
1. Introduction
Type I (T1) diabetes is associated with many complications in-
cluding bone loss (1–12). Approaches to understand the mecha-
nisms accounting for T1 diabetic bone pathology include cell
culture models, human clinical studies, and animal models. Cell
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296culture models allow examination of effects of individual factors,
such as hyperglycemia, on cell parameters such as signaling, re-
sponsiveness, and differentiation. However, tissue pathology is of-
ten caused by a combination of factors that are produced by more
than one cell type. Clinical studies allow examination of systemic
and tissue effects, but are limiting in the types of analyses that can
be done. Animal models are a compromise between clinical and in
vitro studies. They can be genetically manipulated, their diet/en-
vironment can be controlled, and a multitude of analyses can be
performed on them, making animal models powerful tools to un-
derstand mechanisms of tissue pathology, provided that tissue
responses are similar to what is seen clinically.
A variety of T1 diabetic rodent models exist. Some mouse
models become spontaneously diabetic, such as the non-obese di-
abetic (NOD) mice, while other T1 diabetic models are pharma-
cologically induced by compounds such as alloxan, streptozotocin
(STZ), Vacor, Dithizone, and 8-hydroxyquinone (reviewed in
(13)). The streptozotocin-induced diabetes model has been ex-
tensively used, making it particularly useful for building upon
and comparing results of other studies. STZ is a nitrosurea com-
pound derived from Streptomyces achromogenes,w h i c hh a sa l s o
been used as an antibiotic and a cancer treatment. It enters pan-
creatic β cells through glucose transporter 2 (GLUT2) channels in
the plasma membrane and causes cellular toxicity and local im-
mune responses that lead to hypoinsulinemia and hyperglycemia
in animals (14). In some models, especially rats, a single dose of
STZ is effective at inducing T1 diabetes. In mice, however, mul-
tiple low doses (40 mg/kg) are the most effective at maintaining
mouse viability and inducing pancreatic dysfunction in part
through immune destruction. This response is similar to what is
seen during the onset of T1 diabetes in humans (14), although
lymphocytes are not required for STZ induction of diabetes
(15). The benefits of the STZ-induced diabetic mouse model in-
clude that it allows one to induce diabetes in genetically altered
mice, maintain mice in a controlled environment, regularly mon-
itor and directly measure serum and bone factors, obtain bone
samples for high-resolution analyses, and chose the time of diabet-
ic induction (compared to waiting for the diabetes to occur in
spontaneous models).
Examination of bones from STZ-induced diabetic mice dem-
onstrates a significant decrease in bone volume fraction marked by
decreased levels of markers of osteoblast maturation and increased
levels of markers of adipogenesis (16). However, to confirm that
this model is appropriate to study T1 diabetic bone pathology, it
is important to prove that the STZ-injected mice exhibit a bone
phenotype similar to spontaneously T1 diabetic mice and, most
importantly, similar to T1 diabetic humans. Indeed, low multiple
low-dose STZ induction of diabetes causes a bone phenotype
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models such as NOD mice (17), confirming the utility of the
STZ model for studying mechanisms of T1-diabetes-induced
bone loss.
While STZ-induced diabetes produces consistent bone pa-
thologies (i.e., decreased bone density, increased marrow adipos-
ity), we have found that the magnitude of effects can vary (being
greater in some experiments compared to others). We hypothe-
sized that this difference may be related to the activity/strength
of the STZ that we inject. Manufacturer (Sigma) data sheets indi-
cate that STZ is stable for approximately 2 years if frozen (−20°C)
and protected from the light. In solution, STZ is stable around a
pH of 4 and therefore is prepared in cold citrate buffer at a pH of
4.5 to enhance stability. If not used fresh, STZ solutions can ex-
hibit reduced ability to induce diabetes.
In this study, we examined the role of STZ concentration (40
or 60 mg/kg) in multiple dose induction of diabetes, disease se-
verity, and bone loss. Both doses caused a similar level of bone
loss, but the higher dose of STZ caused a more rapid elevation
of blood glucose levels, greater magnitude of change in body
mass, fat pad mass, and bone gene expression (osteocalcin,
aP2). While markers of kidney function appeared normal in all
conditions, liver inflammation was detected in the high-STZ-
dosed mice. An increase in bone cathepsin K and in the
RANKL/osteoprotegrin (OPG) ratio was noted only in the
high-dose group, suggesting that increased diabetes severity
may lead to increased osteoclast activity. This may explain some
of the disparity between existing studies regarding the role of
osteoclasts in diabetic bone pathology.
2. Materials and
Methods
2.1. STZ Induction
of Diabetes
Male BALB/c mice (Harlan Laboratories, Houston, TX, USA),
10 weeks old, were given daily intraperitoneal injections with
STZ (40 or 60 μg/g body weight in 0.1 M citrate buffer) for
5 days to induce diabetes (14, 18) .C o n t r o lm i c ew e r ei n j e c t e d
with buffer alone. Blood glucose levels were examined 7 days af-
ter the final streptozotocin injection by obtaining blood from
the lateral saphenous vein and measuring glucose concentration
with a glucometer (Accu-Check instant, Boehringer Mannheim
Corporation, Indianapolis, IN, USA). Mice with blood glucose
levels greater than 300 mg/dl were considered diabetic. At the
time of harvest, 19 days after the first streptozotocin injection,
blood glucose measurements were again obtained along with to-
298 Motyl and McCabetal body, tibialis anterior, and subcutaneous femoral fat pad
mass. Animal studies were conducted in accordance with the
Michigan State University Institutional Animal Care and Use
Committee.
2.2. Serum Assays Blood was collected at the time of harvest, allowed to clot at room
temperature for 5 min, then centrifuged at 4,000 rpm for 10 min.
Serum was removed and stored at −80°C. Serum went through
no more than two freeze/thaw cycles. Serum osteocalcin was
measured using a mouse osteocalcin EIA kit (BT-470, Biomedical
Technologies, Inc., Stoughton, MA, USA) according to the man-
ufacturer’s protocol. Serum TRAP5b was measured using a
MouseTRAP assay kit (SB-TR103, Immunodiagnostic Systems
Inc., Fountain Hills, AZ, USA) according to the manufacturer’s
protocol.
Serum blood urea nitrogen (BUN), creatinine, and 25-
hydroxyvitamin D were measured at the Diagnostic Center for
Population and Animal Health (DCPAH) at Michigan State Uni-
versity. Because of volume requirements for assays at DCPAH, se-
rum samples had to be pooled. For BUN and creatinine, two
samples were submitted for control and 40-mg/kg dose and
one sample was submitted for the 60-mg/kg dose (each submit-
ted sample contained serum from five different mice). For 25-
hydroxyvitamin D, three samples were submitted for control,
40 mg/kg, and 60 mg/kg groups (each submitted sample
contained serum from one to four mice).
2.3. Mineral
Apposition Rate
Mice were injected intraperitoneally with 200 μlo f1 0m g / m l
calcein (Sigma, St. Louis, MO, USA) dissolved in saline 7 and
2 days before harvest. L3 vertebrae were fixed in formalin at time
of harvest then transferred to 70% ethanol after 24 h. Vertebrae
were then embedded and sectioned at 5 μm on a Reichert Jung
2030 rotary microtome. Sections were photographed under
fluorescent light and the distance between lines of calcein was
measured.
2.4. Micro-computed
Tomography Analyses
Fixed bones were scanned with a calibration standard using a GE
Explore Locus micro-computed tomography system at a voxel
resolution of 20 μm. A threshold of 1,400 was used to separate
bone from bone marrow. Trabecular bone analyses were made
in a region of trabecular bone defined at 0.17 mm under the
growth plate of the tibia extending 2 mm toward the diaphysis
and excluding the outer cortical shell. Bone parameters were com-
puted by a GE Healthcare MicroView software application for vi-
sualization and analysis of volumetric image data.
2.5. RNA Analysis Whole tibiae (or liver) were crushed under liquid nitrogen condi-
tions using a Bessman tissue pulverizer and homogenized (Omni
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reagent solution (Molecular Research Center, Inc., Cincinnati,
OH, USA) and RNA was extracted. RNA integrity was verified
by formaldehyde-agarose gel electrophoresis. Synthesis of com-
plementary DNA (cDNA) was performed by reverse transcription
with 2 μg of total RNA using the Superscript II kit with oligo dT
(12–18) primers according to the manufacturer’s protocol (Invitro-
gen, Carlsbad, CA, USA). cDNA (1 μl) was amplified by poly-
merase chain reaction (PCR) in a final volume of 25 μlu s i n g
the iQ SYBR Green Supermix (Bio-Rad, Hercules, CA, USA)
with 10 pmol of each primer (Integrated DNA Technologies,
Coralville, IA, USA). Osteocalcin was amplified using 5′-ACG
GTA TCA CTA TTT AGG ACC TGT G-3′ and 5′-ACT TTA
TTT TGG AGC TGC TGT GAC-3′ (19). Adipocyte fatty-acid-
binding protein 2 (aP2) was amplified using 5′-GCG TGG
AAT TCG ATG AAA TCA-3′ and 5′-CCC GCC ATC TAG
GGT TAT GA-3′ (20). TRAP5 was amplified using 5′-AAT
G C CT C GA C CT G GG A - 3 ′ and 5′-CGT AGT CCT CCT
TGG CTG CT-3′ (21). Cathepsin K was amplified using 5′-
GCA GAG GTG TGT ACT ATG-3′ and 5′-GCA GGC GTT
GTT CTT ATT-3′ (22). RANKL was amplified using 5′-TTT
GCA GGA CTC GAC TCT GGA G-3′ and 5′-TCC CTC
CTT TCA TCA GGT TAT GAG-3′ according to Zhao et al.
(23). OPG was amplified using 5′-GAA GAA GAT CAT CCA
AGA CAT TGA C-3′ and 5′-TCC ATA AAC TGA GTA GCT
TCA GGA G-3′. IL-1β was amplified using 5′-CAG GAT GAG
G A CA T GA G CA C C - 3 ′ and 5′-CTC TGC AGA CTC AAA
CTC CAC-3′ (24). IL-6 was amplified using 5′-ATC CAG
TTG CCT TCT TGG GAC TGA-3′ and 5′-TAA GCC TCC
GAC TTG TGA AGT GGT-3′.H y p o x a n t h i n e –guanine phos-
phoribosyl transferase (HPRT), which was not modulated under
diabetic conditions, was used as a control for RNA levels; it was
amplified using 5′-AAG CCT AAG ATG AGC GCA AG-3′ and
5′-TTA CTA GGC AGA TGG CCA CA-3′ and exhibited similar
kinetics of amplification compared to other genes examined. Real-
time PCR was carried out for 40 cycles using the iCycler (Bio-
Rad) and data were evaluated using the iCycler software. Each cy-
cle consisted of 95°C for 15 s, 60°C for 30 s (except for osteocal-
cin which had an annealing temperature of 65°C), and 72°C for
30 s. cDNA-free samples, a negative control, did not produce
amplicons. Melting curve and gel analyses (sizing, isolation, and
sequencing) were used to verify single products of the appropriate
base pair size.
2.6. Statistical
Analyses
All statistical analyses were performed using Microsoft Excel data
analysis program for t test analysis. Values are expressed as a
mean±SE.
300 Motyl and McCabe3. Results and
Discussion
3.1. STZ Injection (40
and 60 mg/kg) Effec-
tively Induces Type I
Diabetes in BALB/c
Mice
To test the effect of STZ dose on bone pathology, we injected
10-week-old male BALB/c mice with either 40 or 60 mg of
STZ per kilogram body weight for 5 days. Control mice were
injected with vehicle (citrate buffer) to control for the influence
of any injection stress or buffer-induced effects on the animals.
Monitoring of food intake throughout the study indicated a de-
crease only the day after the first STZ injection by 27% in the mice
treated with 40 mg/kg and by 57% in the mice treated with
60 mg/kg streptozotocin (Fig. 1). There were no significant
changes at any other time point, although at later time points,
food intake began to increase in the STZ-injected mice consistent
with diabetic hyperphagia. Still, the both high- and low-dose
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Fig. 1. Mice exhibit decreased food intake following the first STZ injec-
tion and lose weight despite becoming hyperphagic at later time points.
Top panel, Twenty-four-hour food intake (monitored throughout the exper-
iment) is shown at 1, 11, and 18 days post-injection (dpi) for control (white
bar), 40 mg/kg STZ (low dose, gray bar), or 60 mg/kg STZ mice (high dose,
black bar). Only intake at 1 dpi was significantly decreased. Bottom panel,
Mouse body mass was examined throughout the experiment for control
(white circles), 40 mg/kg STZ (black square), or 60 mg/kg STZ mice (black tri-
angle). All values represent averages±SE. n93 per condition; *pG0.05
compared to control.
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to lose more than the low-dose group (Fig. 1).
In our standard protocol, elevated blood glucose levels
(9300 mg/dl) observed at 12 days post-injection (dpi) are used to
confirm diabetes in mice, while control mice exhibit blood glucose
levels less than 200 mg/dl (not shown). In addition, we measured
blood glucose levels at 4 and 19 dpi. Figure 2 demonstrates that at
19 dpi, both low and high STZ mice averaged blood glucose levels
at or above 500 mg/dl, whereas control mice maintained normal
non-fasting blood glucose levels less than 200 mg/dl. In contrast,
at 4 dpi, only high-dose STZ mice exhibited significantly elevated
blood glucose levels compared to controls. This suggests that the
high-dose treatment induces a more rapid loss of insulin secretion
(and therefore more rapid onset of diabetes) compared to low-dose
treatment. Past studies indicate that the magnitude of STZ induction
of serum glucose, urine volume, and glucosuria can, to some extent,
correlate with dose concentration (25–27). Along these lines, the ef-
fect of STZ on pancreatic beta cells has been shown to be dose-
dependentbyinvitro(28)andinvivo(26)studies.Inthelatterstudy,
a greater number of pancreatic beta cells were shown to remain in
mice after injection with multiple low doses of STZ (40 mg/kg for
5 days) compared to a single high-dose (200 mg/kg STZ) injection.
Another indicator of the severity of diabetogenic and catabol-
ic effects are changes in mouse body parameters (body, muscle,
and fat pad mass), which were significantly decreased in both
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Fig. 2. High-dose STZ treatment causes a greater increase in blood glu-
cose levels at early but not late time points compared to low dose STZ.
Shown are mouse blood glucose levels measured at 4 and 19 days post-
injection (dpi) for control (white bar), 40 mg/kg STZ (low dose, gray bar), or
60 mg/kg STZ mice (high dose, black bar). Values represent the average±
SE. n93 per condition. *pG0.05 compared to control.
302 Motyl and McCabeSTZ-dosed groups compared to controls (Fig. 3)a sp r e v i o u s l y
reported for STZ and spontaneously diabetic mice (17). We also
observed a decrease in liver weight that was only apparent in
high-dose STZ mice and likely the result of reduced glycogen
content. The high STZ dose also caused a significantly greater de-
crease in body and fat pad mass compared to the low STZ dose
(Fig. 3). Similarly, Van Dam et al. (29) and Howarth et al. (27)
demonstrated a STZ dose-dependent decrease in rat body weight.
The loss of fat pad mass that we observe is also consistent with
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Fig. 3. Body, muscle and fat pad mass decreases with both low and high
dose STZ treatment. Body, muscle (tibialis anterior), liver, and fat pad
(subcutaneous femoral fat) weights were measured at 19 dpi for control
(white bar), 40 mg/kg STZ (low dose, gray bar), or 60 mg/kg STZ mice (high
dose, black bar). Values represent the average±SE. n93 per condition. *pG
0.05 compared to control;
ΔpG0.05 compared to 40-mg/kg STZ dose.
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adipocyte lipolysis (30). The increased lipolysis can contribute to
the modest but significant decrease in body weight compared to
low-dose STZ-treated mice.
Next, we examined STZ dose effects on the skeleton. Bone
density analyses at 19 dpi demonstrated, as expected, that STZ-
treated mice lose tibial trabecular bone volume fraction (BVF)
compared to control mice (Fig. 4, images and graph). This is con-
sistent with previous reports in pharmacologically induced and
spontaneously diabetic mice and rats and is consistent with T1 di-
abetic human studies (2–4, 12, 16, 17, 31–50). Interestingly, bone
loss (in contrast to body and fat mass, Fig. 3) was not dependent
upon STZ dose as demonstrated by similar BVF between the low
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Fig. 4. Bonelossisevidentindiabetesinducedbybothlow-andhigh-dose
STZ.Thetwo-dimensionalimagesatthetopwereobtainedfrommicro-com-
puted tomography analyses of representative tibias from control and STZ-
treated mice (40 days post first injection). Three dimensional images were
composed of 760 consecutive slices. The bar graphs indicate the measured
bone volume fraction (average±SE) of the tibial trabecular region and the
tibia lengths of control (white bar), 40 mg/kg STZ (low dose, gray bar), or
60 mg/kg STZ mice (high dose, black bar). n93 per condition. *pG0.05 com-
pared to control.
304 Motyl and McCabeand high STZ groups. Our previous studies, in mice at 16–
20 weeks of age, also demonstrate significant bone loss. Because
the mice in the current study were 10 weeks old and can still ex-
hibit skeletal growth (albeit at a slower rate than younger mice),
we also examined bone length. No changes in tibial length were
observed (Fig. 4), suggesting that T1 diabetes did not alter bone
growth in these mice.
Previously, we demonstrated that low-dose STZ suppresses os-
teoblast markers and activity, so we examined the influence of STZ
dose/diabetes severity on this effect. First, we measured mineraliza-
tionappositionrate.Figure5demonstratesthatthisfunctionalmea-
sure of osteoblast activity (bone formation) is decreased in both low
and high STZ dose diabetic mice. Consistent with this finding, se-
rum osteocalcin levels were decreased in STZ mice, but to a much
greaterextentinhigh-versuslow-dosemice.Tofurtherassesseffects
onosteoblasts,RNAanalysesweredonetoexaminegeneexpression,
which we have found to be an even more sensitive marker for deter-
mining early responses in bone. As shown in Fig. 5, osteocalcin
(OC) messenger RNA (mRNA) levels, a marker of mature osteo-
blasts, are significantly decreased in whole tibias of T1 diabetic mice
compared to controls. High-dose STZ caused a further tenfold re-
ductioninOCRNAlevelscomparedtolow-doseSTZ-treatedmice,
suggesting a relationship to disease severity. The suppression of
osteocalcin expression at the mRNA and/or protein (serum) level
has been seen previously in STZ and spontaneously diabetic mouse
and diabetic rat models (17, 33, 36, 39, 46, 49). However, to our
knowledge,thishasnotbeenshowntobeSTZdose/diseaseseverity
dependent. Previously, we demonstrated a positive correlation be-
tween changes in OC mRNA levels and osteoblast activity (bone
density) (16, 17, 37, 51). However, despite a large difference in
OCmRNAlevels(Fig.5),wedidnotobserveasignificantdifference
in BVF between the two doses of STZ (Fig. 4). We suspect that the
differences in OC mRNA between low and high STZ dose will con-
tinue to impactBVFatlatertimepointssincetherewould beadelay
between changes in osteoblast activity and actual BVF changes.
These RNA findings suggest the utility of gene expression studies
in bone as early indicators of later changes in function.
T1 diabetic bone loss is associated with increased marrow ad-
iposity. Therefore, we examined the mRNA levels of a marker for
mature adipocytes, adipocyte binding protein 2 (aP2, also known
as fatty acid binding protein-4), which correlates with the extent
of bone marrow adiposity (16, 17, 37, 51). Similar to previous
reports in STZ-induced diabetic mice and spontaneously diabetic
mice (16, 17, 37, 51), either dose of STZ increased aP2 expression
in bone, but the magnitude of this increase was significantly great-
er in mice treated with the higher dose of STZ (Fig. 5).
Table 1 demonstrates the similarity of STZ effects on bone to
those of a spontaneous T1-diabetic mouse model, NOD mice. All
Streptozotocin, Type I Diabetes Severity and Bone 305diabetic mice (spontaneous, STZ low dose, STZ high dose) ex-
hibit significant bone loss, decreased osteocalcin expression, and
increased aP2 compared to experimental non-diabetic control
mice. However, there were differences in the magnitude of
changes. In this study, we examined STZ-treated mice at
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Fig. 5. STZ-induced T1-diabetes decreases MAR, serum osteocalcin,
and bone osteocalcin mRNA while increasing aP2 expression. Control
(white bar), 40 mg/kg STZ (low dose, gray bar), and 60 mg/kg STZ mice
(high dose, black bar) were examined at 19 dpi for osteoblast parameters:
mineral apposition rate (MAR; representative fluorescent images of cal-
cein labeling of bone shown at top of figure), serum osteocalcin (OC), and
tibial osteocalcin mRNA levels [expressed relative to hypoxanthine–gua-
nine phosphoribosyl transferase (HPRT), a housekeeping gene). Expres-
sion of a mature adipocyte marker, aP2, was also examined. For all
RNA analyses, expression was expressed relative to control levels which
were set to 1. Values represent the average±SE. n93 per condition, ex-
cept for high STZ dose MAR (n=1). *pG0.05 compared to control;
ΔpG
0.05 compared to 40-mg/kg STZ dose.
306 Motyl and McCabe19 dpi, whereas in our past study in NOD mice, we examined
mice at 40 dpi (17). The latter study included the multiple low-
STZ-dose model which demonstrated a 50% suppression in
BVF at 40 dpi corresponding with changes in NOD mice. Thus,
bone loss at 40 dpi is greater than at 19 dpi. With regard to RNA,
osteocalcin exhibited a 55% decrease in low-STZ-dose mice,
a 70% decrease in diabetic NOD mice, and a 94% decrease
in high-STZ-dose mice compared to controls. The latter large
suppression in osteocalcin expression has not been previously ob-
served. aP2 expression was increased in all models, but high-STZ-
dose mice exhibited less than half the levels seen in NOD mice,
and low STZ dose exhibited even less elevation than high dose.
We have previously observed some variability in the magnitude
of aP2 induction in the low-STZ mice, suggesting that multiple
factors, including hyperlipidemia, inflammation, age (we exam-
ined 13 weeks mice compared to greater than 24 weeks NOD
mice), that can differ between experiments may contribute
to the magnitude of adiposity in diabetic bone. Still, despite all
these differences, both spontaneous and STZ-induced mouse
models lose bone, have decreased osteoblast function and marrow
adiposity.
Next we examined dose/severity effects on markers of osteo-
clast maturation and activity. Levels of serum active TRAP5b, a
marker of active osteoclasts, were decreased in both STZ doses
(Fig. 6), consistent with previous studies suggesting that resorp-
tion is not increased in T1 diabetic humans and rodent models (2,
16, 33, 40, 43, 45, 51–63). We measured serum osteoclast markers
rather than urine markers because diabetes is associated with poly-
uria (which can confound measurements due to large differences
in urine volume between control and diabetic mice) and can po-
tentially result in nephropathy which could affect urine levels of
Table 1
Bone phenotype of spontaneous versus pharmacologic T1-
diabetic mouse models
Percentage of control
40 dpi 19 dpi—STZ dose
NOD (%) Low (%) High (%)
BVF 50 76 69
OC RNA 30 45 6
aP2 RNA 570 140 248
Average diabetic mouse values are expressed as a percent of non-diabetic
mouse values. Differences were all statistically significant (compared to
controls)
Streptozotocin, Type I Diabetes Severity and Bone 307measured factors. We also examined the expression levels of oste-
oclast markers in whole bone RNA. Figure 6 demonstrates that
TRAP5 mRNA levels did not differ between conditions, although
it showed a trend to decrease in high-STZ-treated mice. Differen-
ces between RNA and serum levels may result from differences
between RNA and protein stability and between local and system-
ic measures (the later would be the sum of changes in all bones
which could result in significant differences). Interestingly, we
found that cathepsin K, a protease found in lysosomes and active
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Fig. 6. T1-diabetes decreases serum TRAP5b, while high-dose STZ
increases cathepsin K and RANKL/OPG ratio. Control (white bar),
40 mg/kg STZ (low dose, gray bar), and 60 mg/kg STZ mice (high dose,
black bar) were examined at 19 dpi for osteoclast markers and activity: se-
rum TRAP5b, TRAP5 RNA, cathepsin K RNA, and RANKL/OPG RNA ra-
tio. RNA levels were expressed relative to HPRT. RNA values represent
the average±SE and are expressed relative to control mice (set to 1).
*pG0.05 compared to control.
ΔpG0.05 compared to 40-mg/kg STZ dose.
308 Motyl and McCabein osteoclast bone resorption, was significantly increased in high-
dose STZ mice only. Similarly, the RANKL to OPG ratio is also
increased in high-STZ mice, supporting that under high dose/se-
verity, a local environment may exist that could promote resorp-
tion. The fact that serum TRAP5b levels are not elevated suggests
that under these conditions, osteoclasts are not able to be fully ac-
tivated. This may stem from additional factors in T1 diabetes,
such as high glucose and advanced glycosylation end products,
suppressing osteoclast activation (64, 65). There are some studies
that support an increase in osteoclast activity in diabetic rodent
models (66, 67). Our data suggest that differences in resorptive
markers measured and in disease severity could contribute to dif-
ferences seen between studies (in addition to species, gender, and
age differences).
The exact mechanisms accounting for differences in the mag-
nitude of low- versus high-STZ dose effects are not fully known,
but our data indicate that there are differences in disease onset
(based on earlier blood glucose elevation in high dose mice)
and metabolic/catabolic effects (a greater loss of body and fat
pad mass in high-dose mice) between the two dosing regimes.
The greater loss of fat pad mass in high-dose STZ mice is not only
a disease severity issue. Fat pad loss could cause a proportional
decrease in serum adipokine levels such as leptin, as previously
demonstrated in low-STZ-dose mice (37, 68). In addition, greater
loss of fat pad mass could lead to a greater increase in serum fatty
acids which could in turn stimulate PPARγ2 and induce adipocyte
maturation in the bone marrow at the expense of osteoblast mat-
uration. This possibility is supported by a study where 55 or
100 mg/kg STZ or alloxan was administered to rats and it was
found that only the high dose of either drug caused increased se-
rum triglycerides and cholesterol (69).
It is possible that high doses of STZ are in general more toxic
to the mice. In monkeys, a high dose (100 mg/kg) of STZ was
found to elevate kidney and liver function tests, whereas low-dose
(55 mg/kg) STZ-treated animals had normal kidney and liver
function tests (70). Both doses effectively induced diabetes, but
the low dose did not appear to exhibit toxic effects. Chronic kid-
ney disease (CKD) is a common complication of diabetes and can
also lead to decreased osteoblast and osteoclast function (71).
P a t i e n t sa n da n i m a lm o d e l sw i t hC K Da n dn e p h r o t o x i c i t yh a v e
increased BUN, creatinine, and low vitamin D (71, 72). There-
fore, we measured 25-hydroxy-vitamin D, BUN, and creatinine
levels in the control, low-, and high-STZ-dosed mice. There were
no differences between groups, suggesting that at the STZ doses
we used, kidney damage is not apparent and therefore does not
contribute to the bone phenotype we observed in low- or high-
dose STZ models (Fig. 7). We also examined liver cytokine ex-
pression, which can be a sign of liver toxicity (73), and found that
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Fig. 7. Both low and high STZ dose does not influence kidney function,
but high dose is associated with liver inflammation. Control (white bar),
40 mg/kg STZ (low dose, gray bar), and 60 mg/kg STZ mice (high dose,
black bar) were examined at 19 dpi for markers of kidney function (25-
OH vitamin D, BUN, and creatinine serum levels) and liver toxicity (IL-
1β and IL-6 RNA levels). For serum analyses, samples were pooled to
meet the quantities necessary for measurement. For 25-hydroxyvitamin
D: three samples were analyzed per condition (each sample contained
serum pooled from one to four individual mice). BUN and creatinine anal-
yses were done on one (high dose) or two (control and low dose) blood
samples, each containing serum pooled from five individual mice. IL-6
and C/EBPβ RNA levels were expressed relative to HPRT. Serum values
represent mean±SD. RNA values represent the average±SE and are
expressed relative to control mice (set to 1). *pG0.05 compared to con-
trol;
ΔpG0.05 compared to 40-mg/kg STZ dose.
310 Motyl and McCabeonly high STZ dose treatment caused a significant increase in IL-6
and a trend to increase for IL-1β (Fig. 7). The potential of liver
toxicity is consistent with reduced liver mass (Fig. 3) seen only
in high-STZ-dosed mice.
Takentogether,thisreportdemonstratesthatmultiplelow-dose
STZ-induced T1 diabetic mice exhibit (1) a decrease in body, mus-
cle, and fat pad mass, (2) decreased bone volume, (3) decreased os-
teoblast markers and function, (4) increased marrow adiposity, (5) a
similar bone phenotype to spontaneous mouse models, (6) de-
creasedserumactiveTRAP5b,and(7)nochangeinkidneyandliver
functionmarkers.Moreimportantly,bonelossanddecreasedosteo-
calcin protein are also observed in T1 diabetic patients (2–4, 12, 16,
17, 31–50). High-dose STZ mice exhibit more catabolic effects on
body parameters, suggesting increased disease severity (and second-
ary effects such as liver inflammation). This may play a role in the el-
evationofsomeosteoclastparameters(whicharenotincreasedinthe
lowdosemodel).Whilebothdosescauseboneloss,itisimportantto
correctly choose the dosing regime to be used to obtain consistent
results. Dose response differences may contribute to differences in
the literature and can be capitalized upon and used as a tool to pro-
videinsightintomechanismsregulatingchangesinbonethatarede-
pendent upon disease severity.
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Appendix
Protocols
Streptozotocin Injections
1. Make 0.1 M citrate buffer pH 4.5. For 100 ml, combine
1.05 g citric acid and 1.48 g sodium citrate in dH20. Ensure
pH is 4.5, then bring up to 100 mL with water.
2. Determine weight of the mice and calculate mass of streptozo-
tocin(SigmaS0130)neededforinjectionsof100mlpermouse.
Protocols
Streptozotocin Injections
Streptozotocin, Type I Diabetes Severity and Bone 3113. Quickly weigh streptozotocin, dissolve in cold citrate buffer,
and filter sterilize through a 22-μm pore filter.
4. Immediately draw into a 1.0-mL syringe and inject intraper-
itoneally into mouse. Speed is imperative because streptozo-
tocin degrades rapidly once dissolved.
5. Repeat everyday for 5 days total.
6. Maintain a mouse health score sheet (monitoring body
weight, polyurea, signs of stress, eating habits) regularly
throughout the course of the study.
7. Seven days after the final injection, check fed blood glucose
of the animal.
Determination of Blood
Glucose
1. Hold the mouse firmly by the skin of the back/neck.
2. Shave the inner thigh of one of the hind legs.
3. Put a small amount of petroleum jelly on the shaved area to
help visualize the saphenous vein.
4. Prick the saphenous vein with a 25-gauge needle. A small
drop of blood should form.
5. Measure the blood glucose with an AccuChek Compact
glucometer (Roche).
6. If the blood glucose is greater than 300 mg/dL, the mice are
diabetic. This day is then often considered day 0.
7. Hold clean gauze over the site of the blood draw until bleed-
ing has stopped.
Tissue Isolation
1. Wait until the desired duration of diabetes has passed and eu-
thanize the mice by an approved method.
2. Measure blood glucose immediately after euthanasia if de-
sired or collect serum for a glucose assay.
3. Remove desired organs and bones.
4. Quickly clean bones for RNA or protein extraction of all sur-
rounding muscle and connective tissue and freeze in liquid
nitrogen.
5. Fix bones for micro-computed tomography analyses in for-
malin. Transfer to 70% EtOH after 24 h.
RNA Extraction from Tibia
1. Crush tibia in a Bessman tissue pulverizer under liquid nitro-
gen conditions.
2. Put crushed bone into a 2.0 mL flat bottom microcentrifuge
tube.
Determination of Blood
Glucose
Tissue Isolation
RNA Extraction from Tibia
312 Motyl and McCabe3. Add 1.0 mL TRI reagent solution (Molecular Research Cen-
ter, Inc.).
4. Immediately homogenize and place on ice (Omni Interna-
tional TH homogenizer, Marietta, GA, USA).
5. Continue with RNA extraction according to TRI reagent
protocol.
6. Make cDNA with 2.0 mg RNA, SuperScript II reverse tran-
scriptase kit, and oligo dT(12–18) primers (Invitrogen)
according to the manufacturer’s protocol.
7. Amplify 1.0 μL cDNA to a final volume of 25 mL by PCR
with iQ SYBR Green Supermix (Bio-Rad) and 10 pmol of
desired primer.
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